UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $23

Benzinga Newsdesk www.benzinga.com Positive 85.7%

Neg 0% Neu 0% Pos 85.7%

UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $19 to $23.